Sotera Health CO

Sotera Health Company stockholders elected four Class III directors, approved executive compensation, and ratified its auditor.

Sotera Health Company has amended its First Lien Credit Agreement, reducing interest rate spreads and refinancing term loans.

Sotera Health Company announces the termination of its Stockholders Agreement following a significant share offering by its former private equity sponsors.

Sotera Health announced a CEO transition and reported a strong first quarter of 2026 with significant revenue and Adjusted EBITDA growth, reaffirming its full-year outlook.

Sotera Health Company announced the appointment of Kenneth D. Krause as a Class I director, effective March 16, 2026, following the resignation of Constantine S. Mihas.

Sotera Health's major stockholders are selling 25 million shares at $15.27 each in a secondary offering, with the company receiving no proceeds.

Sotera Health Company reported a 10% increase in net revenues for the first quarter of 2026, driven by growth across its segments, and a return to net income after a loss in the prior year period.

Sotera Health Company reported significant increases in net income and revenues for the third quarter and first nine months of 2025, while actively managing ongoing ethylene oxide tort litigation.

Sotera Health reported increased revenues and Adjusted EBITDA for Q2 2025, but net income declined due to significant Ethylene Oxide litigation settlements.

Sotera Health's first quarter 2025 shows a slight revenue increase, but net loss reported due to litigation settlement and other expenses.

Sotera Health Company's Q3 2024 results show an 8.5% increase in revenue compared to the same period last year, driven by higher volumes and favorable pricing, while also completing a significant debt refinancing.

Sotera Health Company's second quarter 2024 results show revenue growth, but net income is impacted by litigation costs and debt refinancing.

Sotera Health Company reported a 5.7% increase in net revenues to $1,163.6 million for 2025, alongside significant legal settlements and ongoing environmental litigation.

Sotera Health Company's 2024 10-K filing reveals a complex financial landscape, marked by increased revenue but tempered by litigation expenses and debt management activities.

Sotera Health Company, a global provider of sterilization and lab testing services, released its 2023 annual report, highlighting financial performance, legal proceedings, and future outlook.

Director Ann R. Klee was granted 14,970 restricted stock units as part of the Sotera Health Company 2020 Omnibus Incentive Plan.

Sotera Health CEO Alton Shader was granted 579,573 restricted stock units and 101,817 performance-based share appreciation units.

Director Richard G. Kyle was granted 14,970 restricted stock units as part of the Sotera Health Company 2020 Omnibus Incentive Plan.

Director Kenneth D. Krause was granted 14,970 restricted stock units as part of the company's 2020 Omnibus Incentive Plan.

Director Sean Laurence Cunningham was granted 14,970 restricted stock units as part of the company's 2020 Omnibus Incentive Plan.

Director Karen Flynn was granted 14,970 restricted stock units in Sotera Health Co as part of the company's 2020 Omnibus Incentive Plan.

Sotera Health Company has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Sotera Health Company issues a supplement to its definitive proxy statement, clarifying director attendance at board and committee meetings and the 2024 annual stockholder meeting.

Sotera Health Company announces its 2025 Annual Meeting of Stockholders to be held on May 21, 2025, with voting open until May 20, 2025.

Sotera Health sets date for its 2025 Annual Meeting of Stockholders to be held virtually on May 21, 2025, with proposals including director elections and executive compensation approval.

Sotera Health Company released a supplement to its proxy statement to correct errors in board diversity graphics and voting standards for the upcoming annual meeting.

Sotera Health Company's upcoming annual meeting on May 23, 2024, will include voting on director elections, executive compensation, auditor ratification, and an amendment to the company's certificate of incorporation.

BlackRock, Inc. has disclosed a beneficial ownership of 8.4% in Sotera Health Co. as of June 30, 2026.

Warburg Pincus entities have filed an exit notice confirming they no longer hold any shares of Sotera Health Co.

Sachem Head Capital Management has reported a 5.46% beneficial ownership stake in Sotera Health Co.

The Vanguard Group filed an amended Schedule 13G for Sotera Health Co, reporting zero beneficial ownership due to an internal organizational realignment.

Sculptor Capital LP and its affiliates have reported a 7.39% beneficial ownership stake in Sotera Health Company, totaling 21 million common shares.

The Vanguard Group filed an amended Schedule 13G, reporting a 6.76% beneficial ownership in Sotera Health Co common stock as of December 31, 2025.